10:13 AM EST, 11/12/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and the Sarah Cannon Research Institute have expanded their strategic collaboration, aiming to accelerate the development of cancer therapies and to increase clinical trial access for US patients, the company and the institute said Wednesday.

The collaboration seeks to align Bristol Myers's oncology pipeline with the institute's clinical trial delivery model Accelero, which facilitates trial execution across its network of over 200 locations, the company and the institute said.

Bristol-Myers shares were 1.5% higher in recent trading.

Price: 49.46, Change: +0.74, Percent Change: +1.53